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Reperfusion of coronary arteries to limit myocardi- 
al ischemic injury and extent of myocardial necrosis 
is possible by either the use of fibrinolytic therapy, 
coronary angiopiasty or coronary artery bypass 
surgery. The concept that early reperfusion may 
saivage jeopardized myocardium is derived from 
basic experimental studies whieh purported to 
demonstrate that the ultimate extent of irreversible 
myocardial injury could be reduced by reperfusion 
of the ischemic myocardium within 3 hours from 
the onset of regional myocardial ischemia. It is 
firmly established that salvage of ischemic myocar- 
dium is dependent on early restoration of blood 
flow to the myocardium at risk. Respite dependen- 
cy on reoxygenation for ultimate survlval, myocar- 
dial tissue that is reperfused and reoxygenated 
may be subjected to additional injurious insult due 
to reactive metaboiites of oxygen. The cytotoxic 
species of oxygen are referred to as “oxygen free 
radicals.” Cobtcident with the influx of inflamma- 
tory cells into the reperfused region is an additional 
loss of otherwise viable myocardial cells. There is 
strong support for the concept that the poiymor- 
phonuclear leukocyte is a contributor to the phe- 
nomenon of ‘Veperfuslon” or “reoxygenation” in- 
jury in the Mood perfwed heart. This discussion fo- 
cuses on the roie of the neutrophil as a potential 
contributor to the extension of tissue injury and re- 
views those interventions, which although in the 
experimental stage, offer promise of becoming 
therapeutically important in the future and may 
help elucidate the mechanisms underlying the po- 
tentially deleterious roie of the neutrophil in situa- 
tions invoiving whole blood reperfusion of the isch- 
emit myocardium. 
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I t is recognized that prolonged myocardial ischemia is accompanied by a time-dependent loss of the viabil- ity of myocardial cells in the jeopardized region of the 
heart.’ Reperfusion is necessary to initiate and maintain 
those functions responsible for reversal of the changes 
induced by ischemia and for the continued survival of the 
myocardial cells at risk of permanent damage. The devel- 
opment of pharmacologic methods for reperfusion of the 
ischemic heart has reduced mortality and has led to the 
acceptance of thrombolytic therapy as the standard ap- 
proach to the management of patients with an evolving 
acute myocardial infarction.2 
Reperfusion injury has been recognized as occurring 
in experimental models of myocardial ischemia.3 It has 
been assumed that the observed loss of cell viability asso- 
ciated with the reintroduction of oxygen was solely an 
acceleration of cell death in myocytes that were beyond 
the point of salvage, or had been injured irreversibly. 
Reexamination of this question suggests that reperfusion 
of the previously ischemic heart with oxygenated whole 
blood may be detrimental as well as beneficial to the 
myocyte.4-6 A significant effort has been devoted to gain- 
ing a better understanding of the oxygen paradox7 or the 
phenomenon of reperfusion injury,7q8 or both, which may 
be more appropriately referred to as reoxygenation injury 
(i.e., an extension in the loss of myocardial cell viability 
beyond that due to the ischemic process itself). A number 
of recent reviews have been devoted to an examination of 
the question of whether reactive species of oxygen, or 
oxygen free radicals, contribute to the development of 
irreversible myocardial cell injury during the period of 
reperfusion.7-‘0 The purpose of this essay is to focus at- 
tention on the role of the polymorphonuclear leukocyte 
(PMN) as a contributor to the phenomenon of reperfu- 
sion injury and to call attention to factors that modulate 
the inflammatory response to myocardial cell injury. 
NEUTROPHIL-DEPENDENT DAMAGE TO THE 
ENDOTHELiUM AND CARDIAC MYOCYTE 
One of the important functions of the PMN is defense 
of the host organism. However, during altered physiolog- 
ic states, the PMN may react in a manner that leads to 
tissue injury. The tissue damage resulting from myocar- 
dial ischemia activates a sequence of events characterized 
as an inflammatory response that occurs independently of 
any improvement in myocardial reoxygenation. The con- 
cept we propose is that the invading leukocytes and ensu- 
ing inflammatory response contributes to the extension of 
myocardial cell injury adding to the irreversible cell inju- 
ry from the ischemia itself. Interventions directed against 
the inflammatory cells and the cytotoxic products pro- 
duced at the site of myocardial injury may result in a 
reduction in the extent of tissue damage associated with 
myocardial ischemia or reperfusion, or both. The circu- 
lating PMN does not interact with the normal endothelial 
surface of the vasculature. However, the PMN can be 
activated in response to stimuli arising from the ischemic 
insult, either from within or outside of the vascular com- 
partment, and can be induced to undergo shape changes 
and ultimately to adhere to the surface of the vascular 
endothelium. ’ ’ 
Infiltration of the ischemic myocardium by PMNs 
begins within 60 minutes of the onset of regional myocar- 
dial ischemia and increases progressively after the onset 
of reperfusion. l 2-1 4 Neutrophils invade the region of isch- 
emit myocardium long before the transmural progression 
of irreversible injury reaches the subepicardial myocardi- 
al region.15 Reperfusion is essential to prevent further 
extension of ischemia-induced myocyte necrosis. In the 
absence of reperfusion, the slowly developing inflamma- 
tory response to tissue injury permits neutrophil-mediat- 
ed injury to progress and requires 12 hours or more to 
become manifest by histologic examination of myocardi- 
al tissues. Factors involved in the initiation and termina- 
tion of the myocardial inflammatory response are not 
understood in detail, but serve as an interesting target for 
the development of new therapeutic interventions to pre- 
vent extension of tissue injury, either during the ischemic 
period or shortly after reperfusion. 
A number of studiesgel have demonstrated that inter- 
ventions that limit neutrophil function or interfere with 
the cytotoxic factors produced by the infiltrating phagc- 
cytic cells can reduce ultimate infarct size in experimen- 
tal animals that have undergone a period of regional 
myocardial ischemia followed by reperfusion. The role of 
the neutrophil as a contributor to myocardial injury in 
response to ischemia was suggested initially in 1975.17 
Direct studies have demonstrated that ultimate infarct 
size was reduced by 43% in the canine heart under condi- 
tions of neutropenia, compared with control animals sub- 
jected to 90 minutes of regional myocardial ischemia 
followed by reperfusion for 6 hours.5 This observation 
subsequently was confirmed by other investigators using 
alternative means of inducing neutropenia.6 
Additional support for the concept of neutrophil-me- 
diated myocardial injury is derived from the pharmaco- 
logic modulation of neutrophil function during myocardi- 
al ischemia and reperfusion. Recognition of the mecha- 
nism of protection provided by ibuprofen on experimental 
myocardial injury was an important step in addressing 
the role of the neutrophil in promoting reperfusion injury. 
Ibuprofen, in contrast to other inhibitors of cyclooxygen- 
ase, such as indomethacin and aspirin,‘*,‘9 possess myo- 
cardial protective properties without altering myocardial 
blood flow or the relationship between myocardial oxygen 
supply and demand.20,2’ A review of several studies indi- 
cated that of the nonsteroidal anti-inflammatory agents 
examined, only ibuprofen reduced neutrophil infiltration 
to the reperfused myocardium. This observation suggests 
that the PMN contributes to the extension of tissue injury 
on reperfusiorGJj and is in keeping with the original lind- 
ings of Hill and Ward.17 Neither aspirin nor indometha- 
tin reduced infarct size or the in vitro neutrophil respira- 
tory burst in response to stimulation of the PMN with 
Csa. Ibuprofen, however, prevented the complement in- 
duced activation of the PMN and the production of oxy- 
gen radicals.19 It is possible to conclude that ibuprofen, a 
nonsteroidal anti-inflammatory agent, does not exert its 
protective effect on the myocardium through inhibition of 
the cyclooxygenase pathway of arachidonic acid metabo- 
lism, or by altering factors that restore the balance be- 
tween myocardial oxygen supply and demand. 
Additional evidence for the role of the PMN as a 
mediator of reperfusion injury was obtained from studies 
in which prostacyclin, or a related analog, iloprost, as well 
as prostaglandin E’, limited ultimate infarct size in a 
canine model of regional ischemia and reperfusion. The 
mechanism of action was attributed to the ability of the 
prostanoids to inhibit the formation and release of neutro- 
Phil-derived cytotoxic metabolites of oxygen.22m24 Evi- 
dence from a number of studies indicates that the phar- 
macologic inhibition of neutrophil function correlates 
with the observed beneficial effects on myocardial reper- 
fusion injury. 
CHEMOTACTIC FACTORS AND THE 
ACTIVATION AND RECRUITMENT 
OF NEUTROPHILS 
The complement system serves as one of the most 
important sources of inflammatory mediators involved in 
the acute inflammatory response. Complement activation 
generates a potent neutrophil chemotactic factor, CS,. 
This anaphylatoxin has a role in the recruitment of 
PMNs to the site of tissue injury and in their activation. 
Proteolytic enzymes from the plasma and cellular sources 
react with individual complement components resulting 
in the localized formation of inflammatory mediators, 
without causing a generalized activation of the comple- 
ment cascade. The presence of a tissue protease in the 
ischemic myccardium was suggested initially as being 
involved in cleaving the third component of complement 
into chemotactically active fragments that may stimulate 
the attraction of neutrophils to the myocardium.25,26 Car- 
diac lymphatic drainage from the ischemic myocardium 
contains molecules of mitochondrial and subcellular ori- 
gin that are bound to Cl,, which may activate the com- 
plement cascade, promote the release of leukotactic ana- 
phylatoxins, and stimulate the migration of PMNs to 
sites of tissue injury. 27 Depletion of complement with 
cobra venom factor significantly reduced PMN intiltra- 
tion into ischemic myocardium and resulted in a decrease 
in tissue injury associated with regional ischemia and 
reperfusion. 25,28 Complement-derived products can exac- 
erbate ischemic tissue injury and cardiac dysfunction 
through mechanisms that are independent of the pres- 
ence of neutrophils. Neutrophil-independent injury by 
complement may be associated with the vascular actions 
of the Cja, Cda and C&, known to enhance vascular per- 
meability and alter vessel tone. Furthermore, tissue inju- 
ry may be a consequence of the formation of cytolytic 
membrane attack complex (C5b.9), which can result in 
the production of transmembrane channels and facilitate 
the influx of extracellular calcium and disruption of myo- 
cyte function.29 
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adheden molecule-l (ICAM-1) on the edothetial cell membrane thereby serving as an altemate mechanii for the attachment 
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Endothelial cells may be an important source of a 
specific neutrophil chemotactic factor.30 Either interleu- 
kin-l (IL-l) or tumor necrosis factor a (TNF-a) will 
induce, in endothelial cells, the synthesis and secretion of 
a neutrophil chemotactic factor similar in structure to a 
human monocyte-derived neutrophil-activating factor. 
Neutrophil-activating factor will promote neutrophil che- 
motaxis and, in addition, will induce an increase in intra- 
cellular calcium, an oxidative burst, and granule exocyto- 
sis through a guanosine triphosphate-binding protein- 
dependent pathway. Similar responses are observed with 
other chemotactic peptides (e.g., &, formyl-methionyl- 
leucyl-phenylalanine).31 The role that endothelial cell- 
derived mediators may play in activating neutrophils af- 
ter ischemic injury has not been investigated. These rela- 
tionships are important in determining the mechanisms 
that initiate the activation of circulating neutrophils and 
promote their adherence to the injured vascular wall. 
ADHERENCE-PROMOTING CELL SURFACE 
GLYCOPROTEIN COMPLEXES AND 
THE INTERACTION BEIWEEN THE 
GRANULOCYI’ES AND ENDOTHELIAL CELLS 
Granulocytes migrate across the vascular endotheli- 
urn into the extravascular space in response to tissue 
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injury. Initially, the inflammatory cells adhere to the 
vascular endothelial cell. A family of heterodimeric gly- 
coproteins, possessing a common /I subunit of 95 kDa 
(CD18) associated noncovalently with separate (Y sub- 
units of 177,165 and 150 kDa, are present on the neutro- 
Phil. The neutrophil surface glycoproteins are designated 
as lymphocyte function-associated antigen- 1 (LFA- 1) 
(CDlla), Mol or Mac-l (CDllb) and gp150,95 
(CD1 lc), respectively. The Mol glycoprotein hetero- 
dimer is involved in the process of cellular adhesion and 
serves as the receptor for C3bi opsonized particles. 
Distinct stimuli mobilize Mol from intracellular sites 
and lead to its expression on the cell surface. Mol partici- 
pates in adherence of the leukocyte to the endothelial cell 
and to other PMNs, as well as in chemotaxis and spread- 
ing on cell surfaces. An increase up to twofold in Mol 
cell-surface expression has been observed. At least 50% of 
the total population of Mol receptors is located intracel- 
lularly. The increased expression of Mol increases neu- 
trophil adherence to cell surfaces and facilitates chemo- 
taxis. The increase in Mol glycoprotein expression is 
coupled to the release of neutrophil gelatinase which par- 
ticipates in the degradation of connective tissue, thus 
allowing for the passage of neutrophils through capillary 
walls and into the extravascular space. The up-regulation 
of Mol, for which C3bi serves as the ligand, would allow 
for enhanced recognition and attachment to endothelial 
surfaces that have been “opsonized.” Injury to the endo- 
thelium from ischemia and reoxygenation promotes neu- 
trophil adherence to the cell surface. There is enhanced 
binding of neutrophils to endothelial surfaces secondary 
to the interaction of neutrophil CD 18 molecules with the 
intercellular adhesion molecule-l (ICAM-1) on the en- 
dothelial cell membrane.32 Enhanced ICAM- expres- 
sion on the endothelial cell surface can be induced by 
multiple inflammatory mediators including bacterial en- 
dotoxin and the cytokines IL-l, interferon-y, and TNF- 
a.33 A distinct endothelial leukocyte adhesion molecule 
(ELAM-1) that promotes neutrophil binding to the endo- 
thelium can be induced by specific cytokines.34 Whether 
a similar increase in the expression of ELAM- 1, ICAM- 1 
or ICAM-l-like molecules occurs in ischemic endotheli- 
urn is not known, but may play an important role in 
leukocyte localization to ischemic myocardium (Fig. 1). 
It has been observed that specific cytokines will induce 
synthesis and secretion of a neutrophil chemotactic factor 
by endothelial cells. This observation and studies cited 
provide further evidence for an active role of the endothe- 
lial cell in modulating neutrophil activation and recruit- 
ment to ischemic tissues, rather than a “passive” partici- 
pant in the interaction of inflammatory cells with the 
vascular wall. The interaction between endothelial cells 
and PMNs is required for an effective chemotactic re- 
sponse and for some forms of neutrophil-mediated vascu- 
lar injury. This represents an important initial step in the 
sequence of events associated with the acute inflamma- 
tory response. A variety of agonists involved in acute 
inflammation, including thrombin, platelet-activating 
factor and leukotriene Cd, are known to facilitate the 
adherence of neutrophils to the endothelial surface. 
The neutrophil CD1 8 glycoprotein molecules may 
participate in other functions beside cell adhesion and 
chemotaxis. The glycoproteins may be important in the 
transduction of signals from the cell surface to intracellu- 
lar enzymatic regulatory systems as suggested by the 
presence of an extensive intracellular domain providing 
sites for interaction with cytoplasmic proteins and cyto- 
skeletal elements. 
Monoclonal antibodies, specific for either the a! or p 
subunits of Mel, inhibit certain neutrophil/monocyte 
functions, such as the binding of C3bi-opsonized parti- 
cles, and adhesive interactions of neutrophils and mono- 
cytes, including neutrophil aggregation, monocyte/neu- 
trophil adhesion and spreading on substrates (including 
vascular endothelium), and chemotaxis. The leukocytes 
of patients who are genetically deficient in their expres- 
sion of the Mol glycoprotein exhibit an impairment of 
C3bi-particle binding and leukocyte adhesive interac- 
tions. The Mol glycoprotein has a domain that functions 
as the plasma membrane receptor for C3bi(CR3). The 
critical role of neutrophil glycoprotein adhesive receptors 
Mol in the inflammatory response of activated neutro- 
phils is illustrated by the inhibitory effect of specific mon- 
oclonal antibodies on neutrophil-mediated endothelial 
cell injury in a rat lung model of adult respiratory distress 
syndrome35 and neutrophil-dependent vascular injury in 
skin.36 
A monoclonal antibody (904) that binds to the Mol 
leukocyte cell adhesion-promoting glycoprotein CD1 1 b/ 
CD1 8 was administered to open-chest anesthetized dogs 
45 minutes after the induction of regional myocardial 
ischemia. Ischemia was produced by occluding the left 
circumflex coronary artery for 90 minutes followed by 
reperfusion for 6 hours. There was no difference between 
control and antibody-treated groups with respect to arte- 
rial blood pressure, heart rate or coronary blood flow. 
Administration of antibody produced no observable ef- 
fect on circulating neutrophil counts demonstrating that 
antibody-bound neutrophils were not cleared from the 
circulation. Myocardial infarct size, expressed as a per- 
centage of the area at risk of infarction, was reduced by 
46% with anti-MO1 treatment. The area at risk of infarc- 
tion was similar between groups. Accumulation of neu- 
trophils within the myocardium was reduced significantly 
with anti-MO1 treatment.37*38 Similar protective effects 
were obtained in subsequent studies with anti-MO1 
F(ab’)2 fragments in which antibody treatment was 
maintained for 48 hours into the reperfusion period and 
infarct size was determined at 72 hours after reperfusion. 
Figure 2 summarizes the results from studies in which 
treatment with anti-MO1 antibody was associated with a 
significant protective effect regardless of whether infarct 
size was determined after 6 or 72 hours of reperfusion. 
Furthermore, regional myocardial blood flow determina- 
tions indicated that both groups had equal degrees of 
ischemia in the inner two-thirds of the myocardium dur- 
ing the period of coronary artery occlusion. Results with 
the anti-MO1 antibody indicated that the adhesive inter- 
actions of the neutrophil played a central role in neutro- 
Phil-mediated damage and that inhibition of neutrophil 
adhesive interactions can reduce the extent of irreversible 
myocardial damage associated with reperfusion. The re- 
sults are in accord with earlier studies in which myocardi- 
al reperfusion injury was reduced by a variety of interven- 
tions that shared one common property; i.e., they altered 
the ability of the neutrophil to react with its target tissue, 
the ischemically altered myocardial ce11.24,39-41 
The relative contribution of Mol, LFA-1 and pl50,95 
to leukocyte endothelial adhesion is dependent on the 
applied stimulus and the particular inflammatory cell 
involved. Monocytes and granulocytes employ distinct 
subunits of the adhesion-promoting glycoproteins when 
they interact with the vascular endothelium. Mel, as well 
as LFA- 1 and pl50,95, molecules have been shown to be 
involved in leukocyte-endothelial cell adhesion. The ad- 
hesion may be prevented by antibodies directed against 
the specific portion of the heterodimeric surface mole- 
cules.42 Granulocyte adhesion to endothelial cells, by 
means of the CD1 1 /CD18 subunits, varies according to 
the activation state of the granulocyte and endothelial 
cell. It is reported that granulocyte adhesion, promoted 
by activation of the inflammatory cells with PMA, was 
mediated primarily by Mol and that the adhesion was 
not inhibited by antibodies directed against LFA-1 or 
p150,95. Exposure of endothelial cells to recombinant 
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IL-1 permitted each of the subunits to contribute to gran- 
ulocyte adhesion. 42 Current data suggest that the (Y sub- 
unit of each of the 3 heterodimers contains a common 
region in the extracytoplasmic domain which mediates 
the interaction of the leukocyte with the endothelial cell 
or with the subendothelial structures during transmigra- 
tion of leukocytes to regions of tissue injury and inflam- 
mation. 
The data demonstrate that inhibition of neutrophil 
adhesion reduced the extent of myocardial reperfusion 
injury and are in keeping with the proposition that neu- 
trophils serve an important role as mediators of inflam- 
mation, extending myocardial injury beyond that caused 
by the ischemic process itself. The data also support the 
hypothesis that a significant number of myocardial cells 
at risk are viable after a 90-minute ischemic period, but 
then progress to an irreversible state of injury on reperfu- 
sion with the continued accumulation of PMNs. Studies 
from this laboratory 43 have identified a specific “time 
window” in which neutrophils participate in the extension 
of myocardial infarction after ischemia and reperfusion. 
The inhibition of neutrophil activation and accumulation 
in the myocardium over a prolonged period of time (>48 
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hours) is necessary to ensure a beneficial effect on the 
ultimate extension of irreversible myocardial injury. In- 
terventions that have limited pharmacologic half-lives, 
while effective over brief periods of observation, may not 
show protective benefits if given in a single initial dose 
when infarct size is assessed at a period far removed from 
the point of administration of the treatment under study. 
Consideration must be given to the pharmacokinetic 
properties of selected interventions along with the dy- 
namic and progressive nature of myocyte injury. The 
failure to consider the time course of events in myocardial 
ischemic and reperfusion injury may account for the dis- 
cordant results in published reports. To date, published 
reports have failed to document a consistent progression 
of cellular injury attributable to the period of reperfusion 
and distinct from the progressive cell death entirely at- 
tributable to the period of ischemia. 
NEUTROPHILS, OXYGEN RADICALS, 
MYOCARDIAL INJURY AND PROTECTION 
BY FREE RADICAL SCAVENGERS 
Under some conditions of regional myocardial isch- 
emia and reperfusion, neutrophils adhere to the vessel 
wall at sites of inflammation and release toxic products 
capable of damaging the adjacent endothelium and myo- 
cytes within the reperfused region. It is recognized that 
neutrophils can release cytotoxic products extracellularly 
without undergoing destruction themselves. Neutrophils 
can release a variety of mediators capable of promoting 
tissue injury, including proteolytic enzymes, platelet-acti- 
vating factor, arachidonic acid metabolites and activated 
species of oxygen. The last mentioned group of neutro- 
Phil-derived products, superoxide anion (O-Z), hydrogen 
peroxide (H202), hydroxyl anion (*OH) and hypochlo- 
rous anion (OCl-) are significant cytotoxic products 
derived from the metabolism of molecular oxygen on 
perturbation of the PMN. The generation of cytotoxic 
metabolites of oxygen, generated within the microenvi- 
ronment formed between the adherent activated PMNs 
and altered endothelial cells, leads to an increase in vascu- 
lar permeability and myocyte damage. This situation is 
“explosive” on reperfusion as neutrophils are directed and 
attracted to the reperfused region under the influence of 
the local accumulation of chemoattractants. During an 
extended period of regional ischemia of 240 minutes,14 
the stage is set for the neutrophil-mediated inflammatory 
response and injury that involves normal or reversibly 
injured cells and is accelerated by reperfusion of the isch- 
emit region. Reperfusion injury, therefore, involves cells 
that were viable or recoverable up until the time that 
reperfusion was instituted. The extension of cell death, on 
reperfusion of the ischemic myocardium, is mediated by 
the neutrophil-derived cytotoxic products of oxygen me- 
tabolism. In the absence of reperfusion, all cells that are 
ischemic for a sufficiently long period will undergo irre- 
versible changes, and reperfusion is essential for survival 
of the myocytes that are viable up until the time of reper- 
fusion. However, a portion of the still viable myocardial 
cells will undergo further injury due to the cytotoxic 
actions of the reactive species of oxygen. 
Jolly et a144 were the first to provide evidence for the in 
vivo participation of oxygen radicals in myocardial reper- 
fusion injury. They demonstrated that the administration 
of superoxide dismutase (SOD) plus catalase to anesthe- 
tized dogs, subjected to a 90minute interval of regional 
myocardial ischemia followed by reperfusion, reduced 
ultimate infarct size when the scavenger enzymes were 
administered either before the induction of regional myo- 
cardial ischemia or 15 minutes before myocardial reper- 
fusion. However, the enzymes were without beneficial 
effect if they were infused 40 minutes after reperfusion 
had been instituted. The data suggested that an extension 
of myocardial injury, in addition to that associated with 
the ischemia-induced myocardial cell death, occurred 
very early in reperfusion, and myocyte damage was atten- 
uated by pretreatment with appropriate antioxidants. 
Subsequent studies have demonstrated that SOD, with- 
out the addition of catalase, was equally effective in pre- 
venting the extension of myocardial injury, thereby impli- 
cating superoxide anion as the primary mediator of the 
myocardial damage associated with reperfusion. The rel- 
atively short pharmacologic half-life (6 to 10 minutes) of 
SOD is a drawback to the study of the scavenger in 
experimental protocols that are extended several days 
after reperfusion. Neutrophil chemoattraction to the is- 
chemically injured myocardium and the local formation 
of neutrophil-derived reactive species of oxygen will con- 
tinue to effect a cytotoxic influence on the viable myocar- 
dial cells in the reperfused tissue. The free radical-in- 
duced injury is initiated on reperfusion and continues 
until mechanisms, still to be elucidated, bring about a 
cessation of the inflammatory response. 
Disagreement regarding the cardioprotective role of 
SOD may relate to the use of different durations for 
induction of ischemic injury and reperfusion. To investi- 
gate this concept we undertook studies that used a modi- 
fied form of SOD in which the enzyme was conjugated to 
polyethylene glycol (PEG-SOD).45 The conjugated form 
of SOD has a pharmacologic half-life of 30 hours. Signif- 
icant plasma SOD activity was demonstrated in the dog 
up to 7 days after a single intravenous administration of 
1,000 U/kg of PEG-SOD. Two protocols, differing in the 
mode of administration and duration of the reperfusion 
interval, were used. Dogs were subjected to occlusion of 
the circumflex coronary artery for 90 minutes, then re- 
perfused for either 6 hours (protocol A) or for 4 days 
(protocol B). The dogs received either PEG conjugated to 
albumin (PEG-ALB) or PEG-SOD, 1,000 U/kg. In pro- 
tocol A, treatment was administered starting 15 minutes 
before coronary artery occlusion and continued for 2 
hours, terminating 15 minutes after reperfusion. Infarct 
size was determined 6 hours later. In protocol B, the 
conjugated proteins were given 15 minutes before reper- 
fusion and ended simultaneously with reperfusion. In- 
farct size was measured after 4 days. A significant reduc- 
tion in myocardial infarct size, expressed as a percent of 
the area at risk, was observed in protocol A in the group of 
dogs that received PEG-SOD compared with the PEG- 
ALB-treated controls. Likewise, in the extended proto- 
col, in which infarct size was determined 4 days after 
reperfusion, the PEG-SOD-treated group had a signifi- 
cant reduction in ultimate infarct size (Fig. 3). Hemody- 
namic variables did not differ during the period of coro- 
nary artery occlusion. The respective collateral blood 
flows to the inner two-thirds of ischemic myocardium, 
determined 60 minutes after occlusion, did not differ 
between the groups. Infarct size was inversely related to 
collateral blood flow in the PEG-ALB-treated group. 
The regression line describing the relationship between 
the extent of irreversible myocardial injury and collateral 
blood flow was shifted downward (analysis of covariance, 
p = 0.01) in the group of dogs treated with PEG-SOD. 
With use of the mean collateral blood flow to the inner 
two-thirds of the ischemic myocardium as a covariate, 
infarct size, expressed as a percentage of the area at risk, 
was smaller for the PEG-SOD-treated group than for the 
PEG-ALB-treated group (p <0.05). The data demon- 
strated that PEG-SOD achieved a reduction in ultimate 
infarct size when quantitation of myocardial injury was 
performed after 4 days of reperfusion, a time when the 
plasma SOD activity was maintained well above that 
found in the PEG-ALB control group. These data are 
consistent with studies cited which demonstrated the ne- 
cessity to suppress neutrophil function up to 48 hours to 
effect and maintain a reduction in infarct size determined 
THE AMERICAN JOURNAL OF CARDIOLOGY MAY 22, 1990 19 1 
A SYMPOSIUM: THE RENIN-ANGIGTENSIN SYSTEM -TISSUE SPEClFlC ISSUES 
60 
SUSTAINED PROTECTIVE EFFECT OF PEG-SOD 
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at 72 hours.43 These observations support the hypothesis 
that a critical “time window” exists during which anti- 
neutrophil or antioxidant therapy, or both, must be main- 
tained to effect a reduction in the ultimate extent of the 
infarcted myocardium after periods of ischemia and re- 
perfusion. PEG-SOD may have efficacy over that of the 
native enzyme because of its continued presence in the 
circulation and its ability to adhere to the surface of the 
vascular endothelium. PEG conjugation of SOD en- 
hances cell association and uptake of the enzyme in a 
manner that renders the vascular endothelium more oxi- 
dant resistant. 
The vulnerability of the endothelium to injury from 
reactive species of oxygen may be related to a number of 
factors, which include anatomic proximity to activated 
and invading inflammatory cells and localization of xan- 
thine oxidase activity within endothelial cells. Vascular 
endothelial cells subjected to an ischemic equivalent of 
anoxic incubation followed by reoxygenation become ef- 
fective generators of oxygen free radicals as determined 
by electron paramagnetic resonance measurements with 
a spin trap agent, 5,5-dimethyl-l-l-pyrroline-l-oxide.46 
SOD or catalase abolished the radical signal, suggesting 
that oxygen is sequentially reduced from 02 to Hz02 to 
*OH. Attenuation of the free radical signal by oxypurinol 
suggested that xanthine oxidase was a major source of the 
superoxide anion. It is conceivable that on reperfusion of 
the ischemic myocardium, the endothelial cells, as well as 
the adherent and infiltrating neutrophils, may provide the 
initial source of cytotoxic species of reduced oxygen and 
that the subsequent inflammatory process, involving the 
continued migration and accumulation of PMNs to the 
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injured myocardium, provides a sustained source of oxy- 
gen radicals that diminish with time as reparative pro- 
cesses occur. 
Interpretation of data based on inhibition of free radi- 
cal production by pharmacologic inhibition of xanthine 
oxidase are cautioned. Recent data suggest that the rate 
of conversion of the dehydrogenase form of the enzyme to 
the oxidase form, in the rat heart, is too slow to account 
for the observed results.47 It has been reported that allo- 
purinol scavenges *OH at rates comparable to those of 
mannitol.4s Oxypurinol, the active metabolite of allopuri- 
nol, is more effective as a scavenger of *OH. Time-depen- 
dent formation of the active metabolite in animals pre- 
treated with alIopurino1 may explain the failure of some 
investigators 49 to observe a protection of the ischemic 
myocardium when the drug was evaluated acutely, as 
opposed to studies in which a pretreatment regimen was 
used permitting accumulation of the metabolite, oxypur- 
inol, in which a reduction in ultimate infarct size was 
reported.so~51 Furthermore, oxypurinol combines with the 
myeloperoxidase-derived oxidant, hypochlorous acid, 
preventing the latter from inactivating cul-protease inhibi- 
tor and thereby protecting inflamed tissues from the 
damaging effects of elastase.48 
OTHERFREERADICALSCAVENGERS 
IN THE PREVENTION OF MYOCARDIAL 
REPERFUSION INJURY 
Previous studies have shown that sulfhydryl-contain- 
ing compounds, including mercaptoproprioyl glycine 
(MPG), are capable of reacting with free radicals and 
inhibiting their biologic effects.52g53 Mitsos et aP4 report- 
ed the in vitro free radical-scavenging effects of MPG, as 
well as its potential to reduce myocardial infarct size in 
the canine heart subjected to 90 minutes of regional isch- 
emia followed by 6 hours of reperfusion. The free radical 
scavenger was effective when administered intravenously 
just before the onset of reperfusion, suggesting that the 
sulfhydryl compound protects against that component of 
myocyte injury associated with reperfusion. Related ob- 
servations regarding the cardioprotective effects of MPG 
have been provided by other investigators who have ex- 
amined the phenomenon of myocardial stunning. It was 
noted that SOD, as well as MPG, were equally effective 
in restoring regional contractile function to the heart 
made ischemic for a brief period (15 minutes) followed by 
reperfusion.s5,56 The administration of the scavengers 
was effective when given before the onset of ischemia or 
immediately before reperfusion. If administration was 
delayed after the start of reperfusion, no benefit was 
demonstrated. These findings are reminiscent of the ini- 
tial studies with SOD4 in which salvage of myocardial 
tissue was accomplished only if the scavenger had been 
given before the onset of reperfusion. 
The recognition that sulfhydryl-containing com- 
pounds could scavenge oxygen free radicals and provide a 
degree of protection against myocardial reperfusion inju- 
ry and myocardial stunning led Westlin and Mullanes7 to 
explore the cardioprotective actions of other sulfhydryl- 
containing compounds. Several angiotensin-converting 
enzyme (ACE) inhibitors were examined for their ability 
to suppress superoxide anion formation in vitro and to 
improve postischemic cardiac function in vivo in a canine 
model of regional myocardial ischemia and reperfusion. 
Three sulfhydryl-containing ACE inhibitors, captopril, 
its stereoisomer SQ 14,534, and an analog, zofenopril 
(SQ 27,703) were compared with enalaprilat and tepro- 
tide. The latter 2 agents lack the sulfhydryl group, but 
inhibit ACE. Two additional sulfhydryl-containing com- 
pounds, MPG and N-acetylcysteine (NAC), which are 
not ACE inhibitors, were studied for suppression of free 
radical formation in vitro. The autooxidation of epineph- 
rine to adrenochrome is mediated by superoxide anions 
and was inhibited by captopril, SQ 14,534, and zofeno- 
pril, with similar IC50 values of 8 to 10 PM, but not 
enalaprilat or teprotide (ICss greater than 1,000 PM). 
The autooxidation reaction is inhibited as well by MPG 
and NAC. Captopril, MPG or NAC, but not teprotide or 
enalaprilat, were shown to scavenge superoxide anion 
production by the purine-xanthine oxidase reaction and 
by canine-activated neutrophils. Therefore, captopril 
scavenges superoxide anions in vitro independent of an 
action on ACE, an action that is most likely related to the 
presence of a sulfhydryl moiety. Pretreatment of dogs 
with captopril, intravenously (5 mg/kg), before occlusion 
of the coronary artery for 15 minutes followed by reperfu- 
sion resulted in a 40 to 60% return to active shortening 
within 60 minutes of reperfusion. However, equihypoten- 
sive doses of enalaprilat did not improve segmental func- 
tion during reperfusion. Dogs given captopril immediate- 
ly before restoring coronary blood flow had a similar 
return of function as that observed in dogs treated with 
the drug before occlusion. SQ 14,534, the isomer of cap- 
topril, which is loo-fold less potent as an ACE inhibitor, 
but equipotent in scavenging superoxide anions, also im- 
proved reperfusion-induced cardiac dysfunction when ad- 
ministered at reperfusion (5 mg/kg). Captopril improved 
postischemic contractile derangements by a mechanism 
independent of ACE inhibition. Restoration of blood sup- 
ply to the ischemic myocardium provoked ventricular 
fibrillation in 37.5% of control dogs, but in only 9% of 
those administered enalaprilat and 0% of captopril-treat- 
ed dogs. SQ 14,534 did not reduce the incidence of ven- 
tricular fibrillation (40%), indicating that the antifibrilla- 
tory actions may be related to ACE inhibition, or to a 
direct effect of the free radical scavenger on the integrity 
of the coronary vascular endothelium and the preserva- 
tion of regional coronary artery blood flow. 
CONCLUSIONS 
Regardless of the cellular site of generation (endothe- 
lial cell, neutrophil or other cellular loci), the role of 
reactive species of oxygen in mediating cellular injury 
associated with reperfusion has gained wide support 
through a number of studies that have been reviewed 
recently.58-61 These studies have not always been in 
agreement with the concept that reperfusion of the isch- 
emit myocardium may result in an extension of injury 
beyond that which has resulted from the ischemic insult 
itself. We have concluded that the failure to obtain agree- 
ment among laboratories is related to differences in the 
models used with respect to the instrumentation of the 
heart in chronic animal studies, the duration of occlusion 
(40 vs 90 minutes), and the duration of reperfusion (6 
hours vs 4 days).43 The pharmacokinetic properties of 
interventions used to modify the extent of reperfusion 
injury must be given special consideration because the 
neutrophil-mediated component of reperfusion injury 
may be operative for several days.46 Studies reporting 
negative effects with native SOD may be related to the 
short half-life of its free radical-scavenging capacity, 
which compromises the chances of observing a protective 
effect after 4 days of reperfusion.45 This concern is appli- 
cable to other interventions studied in animal models in 
which assessment of efficacy is made several days after 
cessation of the treatment regimen. Because the PMN is 
implicated as being a major contributor to the observed 
injury on reperfusion, it is essential that the applied stim- 
ulus (ischemia) required for the ultimate chemoattrac- 
tion of the PMN to the reperfused region be of sufficient 
duration. Short ischemic intervals (40 minutes), as op- 
posed to longer (90 minutes) times of ischemic injury, 
may not serve as a sufficient stimulus for neutrophil re- 
cruitment,14 thus making it unlikely that interventions 
designed to mitigate against the deleterious effects of 
neutrophil-dependent cytotoxic products will manifest 
their therapeutic effect. 62 The time-dependent relation- 
ship between the duration of regional myocardial isch- 
emia and the manifestation of reperfusion injury has been 
suggested by the study of Eng et aF3 and must be taken 
into consideration in the design of an experimental proto- 
col for the study of reperfusion injury and its modification 
by pharmacologic interventions. The ability of infarct 
expansion to develop late in the reperfusion period must 
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be recognized.64g65 The modulation of the extent of reper- 
fusion injury with an intervention possessing a relatively 
short pharmacologic half-life in relation to the period of 
reperfusion must be appreciated in the protocol design.45 
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